Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on April 21, 2025
Apellis Announces Craig Wheeler to Join the Board of Directors
GlobeNewswire
·
April 21, 2025
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective …
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
GlobeNewswire
·
April 21, 2025
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D. retired from his role as Immunovant CEO and Director Leadership change is part of a broader …
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire
·
April 21, 2025
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger …
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
GlobeNewswire
·
April 21, 2025
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “ …
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire
·
April 21, 2025
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger …
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
GlobeNewswire
·
April 21, 2025
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 ( …
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
GlobeNewswire
·
April 21, 2025
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
HepatoBurn Reviews 2025 (EXPERT OPINION) Does This Mysterious Red Phenol Formula Deliver Real Results?
GlobeNewswire
·
April 21, 2025
ALBANY, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- HepatoBurn is a natural weight loss formula that optimizes the major fat-burning processes in the body to eliminate stubborn body fat. What makes HepatoBurn revolutionary is its research-backed focus on the …